EP1587955A4 - Differenzialdiagnose-marker und verfahren zu ihrer verwendung - Google Patents

Differenzialdiagnose-marker und verfahren zu ihrer verwendung

Info

Publication number
EP1587955A4
EP1587955A4 EP03810896A EP03810896A EP1587955A4 EP 1587955 A4 EP1587955 A4 EP 1587955A4 EP 03810896 A EP03810896 A EP 03810896A EP 03810896 A EP03810896 A EP 03810896A EP 1587955 A4 EP1587955 A4 EP 1587955A4
Authority
EP
European Patent Office
Prior art keywords
markers
methods
differential diagnosis
diagnosis
differential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03810896A
Other languages
English (en)
French (fr)
Other versions
EP1587955A2 (de
Inventor
Kenneth F Buechler
Alan Maisel
Joseph Michael Anderberg
Paul H Mcpherson
Jeffrey R Dahlen
Howard J Kirchick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/330,696 external-priority patent/US7713705B2/en
Priority claimed from US10/371,149 external-priority patent/US20030199000A1/en
Priority claimed from US10/603,891 external-priority patent/US20040253637A1/en
Priority claimed from US10/673,077 external-priority patent/US20040209307A1/en
Priority claimed from US10/714,078 external-priority patent/US20040219509A1/en
Application filed by Biosite Inc filed Critical Biosite Inc
Priority to EP07107064A priority Critical patent/EP1867734A1/de
Publication of EP1587955A2 publication Critical patent/EP1587955A2/de
Publication of EP1587955A4 publication Critical patent/EP1587955A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03810896A 2002-12-24 2003-12-23 Differenzialdiagnose-marker und verfahren zu ihrer verwendung Withdrawn EP1587955A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07107064A EP1867734A1 (de) 2002-12-24 2003-12-23 Differenzialdiagnose-Marker und Verfahren zu ihrer Verwendung

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US714078 2000-11-16
US43630102P 2002-12-24 2002-12-24
US436301P 2002-12-24
US10/330,696 US7713705B2 (en) 2002-12-24 2002-12-27 Markers for differential diagnosis and methods of use thereof
US330696 2002-12-27
US371149 2003-02-20
US10/371,149 US20030199000A1 (en) 2001-08-20 2003-02-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US603891 2003-06-24
US10/603,891 US20040253637A1 (en) 2001-04-13 2003-06-24 Markers for differential diagnosis and methods of use thereof
US10/673,077 US20040209307A1 (en) 2001-08-20 2003-09-26 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US673077 2003-09-26
US10/714,078 US20040219509A1 (en) 2001-08-20 2003-11-14 Diagnostic markers of stroke and cerebral injury and methods of use thereof
PCT/US2003/041453 WO2004059293A2 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07107064A Division EP1867734A1 (de) 2002-12-24 2003-12-23 Differenzialdiagnose-Marker und Verfahren zu ihrer Verwendung

Publications (2)

Publication Number Publication Date
EP1587955A2 EP1587955A2 (de) 2005-10-26
EP1587955A4 true EP1587955A4 (de) 2007-03-14

Family

ID=32686403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03810896A Withdrawn EP1587955A4 (de) 2002-12-24 2003-12-23 Differenzialdiagnose-marker und verfahren zu ihrer verwendung

Country Status (5)

Country Link
EP (1) EP1587955A4 (de)
JP (1) JP2006526140A (de)
AU (1) AU2003302340B8 (de)
CA (1) CA2511501A1 (de)
WO (1) WO2004059293A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
CN1829730A (zh) 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
EP1565570A4 (de) 2002-11-12 2005-12-28 Becton Dickinson Co Sepsis- oder sirs-diagnose mittels biomarkerprofilen
WO2007008690A2 (en) * 2005-07-08 2007-01-18 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2
EP1519194A1 (de) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
SI1747015T1 (sl) * 2004-04-26 2012-11-30 Janssen Biotech Inc Postopek biopanninga raztopinske faze z uporabo genetsko proizvedenih vabnih proteinov
TR200700896T1 (tr) 2004-07-23 2007-04-24 Aspenbio, Inc. Apandisit teşhisine ilişkin yöntem ve cihazlar
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
DE102004041659A1 (de) * 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
CN101120256A (zh) * 2005-02-17 2008-02-06 霍夫曼-拉罗奇有限公司 Nt-原anp/nt-原bnp的比值用于诊断心功能障碍的用途
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
CA2610910A1 (en) * 2005-06-09 2006-12-21 Paul H. Mcpherson Methods and compositions for the diagnosis of venous thromboembolic disease
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP1904846A4 (de) * 2005-06-29 2009-03-18 Rules Based Medicine Inc Verfahren und kits zur diagnose von akutem koronarsyndrom
WO2007007177A2 (en) * 2005-07-14 2007-01-18 Inverness Medical Switzerland Gmbh Mitochondrial markers of ischemia
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
JP2007082433A (ja) * 2005-09-20 2007-04-05 Niigata Univ 悪性脳腫瘍マーカー遺伝子およびその用途
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
EP1963527A2 (de) * 2005-12-15 2008-09-03 Becton, Dickinson and Company, Wagner, Jaconda Sepsisdiagnose
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2007233320B2 (en) * 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1845379A1 (de) * 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Mittel und Verfahren zur Differenzierung kardialer und pulmonaler Ursachen von Atemnot
EP2021495A4 (de) 2006-05-09 2009-06-24 Musc Found For Res Dev Nachweis von diastolischer herzinsuffizienz durch erstellung von protease- und proteaseinhibitor-plasmaprofilen
DE102006023175A1 (de) 2006-05-17 2007-11-22 B.R.A.H.M.S Aktiengesellschaft In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
EP1882947A1 (de) * 2006-07-28 2008-01-30 F. Hoffmann-La Roche AG Mittel und Verfahren zur Unterscheidung von herz- und lungenbedingten Ursachen für akute Atemnot
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP1909206A1 (de) * 2006-09-11 2008-04-09 Roche Diagnostics GmbH Messbereichserweiterung chromatografischer Schnellteste
DE602006010705D1 (de) * 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemische Marker für akute Lungenembolie
US8449864B2 (en) 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
EP2095106B1 (de) 2006-11-14 2013-03-20 Alere San Diego, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenarterienstenose
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
SE532103C2 (sv) 2006-12-12 2009-10-27 Knut Johansen Metod för att bestämma hälsostatus från analyter i vätskeprover
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2019318A1 (de) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Proteinmarker für kardiovaskuläre Ereignisse
EP2020603A1 (de) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien
ATE533061T1 (de) 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2031397A1 (de) 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactantproteine B und D bei der Unterscheidung der Ursachen für Atemnot
US7955822B2 (en) 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US8852893B2 (en) 2007-09-14 2014-10-07 Physicians Choice Laboratory Services, Llc Detection of nucleic acids and proteins
JP5010034B2 (ja) 2007-12-28 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー 生理学的状態の評価
CN102037355A (zh) * 2008-03-04 2011-04-27 里奇诊断学股份有限公司 基于多重生物标记物板块诊断和监测抑郁症
CN102089654A (zh) * 2008-03-10 2011-06-08 莱恩进公司 Copd生物标志标签
EP2272044A4 (de) * 2008-03-12 2011-07-06 Ridge Diagnostics Inc Entzündungsbiomarkierungen zur überwachung von depressionserkrankungen
US7776522B2 (en) 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
EP2318844A1 (de) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz
EP3336551B1 (de) 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Verfahren für den nachweis von biomarkern und test für neurologische erkrankung
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
WO2010017972A1 (en) * 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
JP5219048B2 (ja) * 2008-09-17 2013-06-26 独立行政法人農業・食品産業技術総合研究機構 抗豚インターロイキン−１８抗体を用いた動物のストレス評価方法
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
WO2010046136A1 (en) * 2008-10-24 2010-04-29 B.R.A.H.M.S. Ag Prognosis and risk assessment in stroke patients by determining the level of marker peptides
WO2010059709A2 (en) * 2008-11-18 2010-05-27 Ridge Diagnostics, Inc. Metabolic syndrome and hpa axis biomarkers for major depressive disorder
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US20120149131A1 (en) 2009-08-28 2012-06-14 B.R.A.H.M.S Gmbh Procalcitonin for the prognosis of adverse events
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20130096052A1 (en) * 2010-03-08 2013-04-18 B.R.A.H.M.S Gmbh Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
US8703424B2 (en) 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
WO2011139914A1 (en) * 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
JP2013525820A (ja) 2010-05-06 2013-06-20 シングレクス、インコーポレイテッド 関節リウマチの発症に関するリスクを診断し、病期分類し、予測し、治療レスポンダーを同定するための方法
EP2598887B1 (de) * 2010-07-28 2015-08-19 Abbott GmbH & Co. KG Verfahren für den nachweis eines ischämischen schlaganfalls
WO2012065095A2 (en) * 2010-11-11 2012-05-18 Medical University Of South Carolina Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
EP2492691A1 (de) 2011-02-22 2012-08-29 Institut de Recerca Hospital Universitari Vall d'Hebron Verfahren zur Vorhersage des Verlaufs eines Patienten mit einem neurovaskulären Krankheit
ES2578477T3 (es) 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
KR101894417B1 (ko) 2011-05-09 2018-09-03 세키스이 메디칼 가부시키가이샤 가용성 lr11의 면역학적 측정방법
RU2469332C1 (ru) * 2011-10-12 2012-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики бронхиальной астмы
EP3088900B1 (de) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin als marker für intermittierendes vorhofflimmern
WO2013079567A2 (en) * 2011-12-01 2013-06-06 Roche Diagnostics Gmbh Nt-proanp and nt-probnp for the diagnosis of stroke
EP3540440B1 (de) 2011-12-08 2022-09-28 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus
EP2597465A1 (de) * 2012-06-26 2013-05-29 Roche Diagniostics GmbH TnT und H-FABP zur Diagnose der Herzschädigung bei einer Infektion
ES2774288T3 (es) 2012-11-09 2020-07-20 Hoffmann La Roche Diagnóstico basado en TnT o BNP de fibrilación auricular paroxística
US9295393B2 (en) 2012-11-09 2016-03-29 Elwha Llc Embolism deflector
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
EP2951318A4 (de) * 2013-02-01 2016-08-17 Univ West Virginia Biomarkeralgorithmus zur bestimmung der zeit des einsetzens eines schlaganfallsymptoms und verfahren
KR101494882B1 (ko) 2013-02-21 2015-02-25 한국과학기술연구원 급성 심근 경색 진단용 조성물, 그 조성물을 포함하는 급성 심근 경색 진단용 키트 및 급성 심근 경색 진단 방법
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
GB201309928D0 (en) * 2013-06-04 2013-07-17 Randox Lab Ltd Method
EP3022322A4 (de) 2013-07-17 2017-05-17 The Johns Hopkins University Multiprotein-biomarkertest für den nachweis von hirnläsionen und ergebnis
WO2015028671A1 (en) * 2013-08-30 2015-03-05 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
FR3010187A1 (fr) * 2013-09-05 2015-03-06 Ct Hospitalier Universitaire Rouen Utilisation de l'urotensine ii et/ou l'urp comme marqueurs pour le diagnostic du vasospasme post hsa
WO2015042465A1 (en) * 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
AU2014351090A1 (en) * 2013-11-15 2016-06-16 Otago Innovation Limited Biomarker for cardiac disorders
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2015179777A2 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
CA2949959C (en) 2014-05-22 2026-07-21 Northwestern University Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
EP3146077A4 (de) 2014-05-22 2018-05-02 The Scripps Research Institute Molekulare gewebesignaturen von nierentransplantatabstossungen
US11371096B2 (en) 2014-10-22 2022-06-28 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
US10690681B2 (en) 2015-03-06 2020-06-23 Washington University Methods to detect myocardial injury and uses thereof
WO2017067821A1 (en) * 2015-10-22 2017-04-27 Universite Pierre Et Marie Curie (Paris 6) A method for determining presence or risk of hemostasis disorder
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
KR101801092B1 (ko) 2016-01-28 2017-11-28 순천향대학교 산학협력단 특발성 페섬유증 진단용 마커 조성물 및 특발성 폐섬유증 진단을 위한 정보제공방법
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
CN108728525B (zh) * 2017-04-19 2021-06-22 香港中文大学 蛛网膜下腔出血的循环microRNA生物标记物和其应用
BR112019026389A2 (pt) * 2017-06-13 2020-07-21 F. Hoffmann-La Roche Ag método para diagnosticar a fibrilação atrial paroxística, método para auxiliar no diagnóstico de fibrilação atrial paroxística e seus usos
EP3655545B1 (de) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarker für intrakranielles aneurysma
CN109975548B (zh) * 2018-03-08 2020-08-07 中山大学 IgG4检测试剂在制备结直肠癌诊断剂方面的应用
EP3762729A1 (de) 2018-03-08 2021-01-13 Meso Scale Technologies, LLC Genetische marker- und/oder biomarker für traumatische hirnverletzung und ultraempfindliche tests für biomarker von traumatischen hirnverletzungen
EP3779452B1 (de) * 2018-03-30 2023-05-03 National Center of Neurology and Psychiatry Verfahren und methode zur bestimmung des schweregrades von neonataler hypoxisch-ischämischer enzephalopathie
EP3553525A1 (de) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnose von leichter oder fortgeschrittener parodontose
EP3553524A1 (de) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis-diagnoseverfahren, verwendungen und kits
EP3553518A1 (de) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis-diagnoseverfahren, verwendungen und kits
EP3553526A1 (de) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Verfahren, verwendungen und kits zur überwachung oder vorhersage der reaktion auf eine periodontale krankheitsbehandlung
EP3553520A1 (de) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Verfahren, verwendungen und kits zur überwachung oder vorhersage der reaktion auf eine periodontale krankheitsbehandlung
EP4465051A3 (de) * 2018-05-29 2025-01-22 Cognizance Biomarkers, Inc. Biomarker und verfahren zur beurteilung und behandlung von epileptischen vs nichtepileptischen anfällen / keine anfälle / psychogene nichtepileptische anfälle
IT201800007264A1 (it) * 2018-07-17 2020-01-17 Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari
JP7398226B2 (ja) * 2019-09-03 2023-12-14 浜松ホトニクス株式会社 大腸がん罹患のリスクを評価するための方法
IL293728A (en) 2019-12-11 2022-08-01 Ichilov Tech Ltd Non-invasive assay for differentiating between bacterial and viral infections
JP7825829B2 (ja) * 2020-04-02 2026-03-09 国立大学法人大阪大学 間質性肺炎の予防または治療用製剤
CN114015759B (zh) * 2020-07-24 2022-08-19 首都医科大学附属北京天坛医院 用于急性缺血性脑卒中预后或复发预警评估的生物标志物及其应用
CN113252910B (zh) * 2021-06-29 2022-05-17 中国人民解放军军事科学院军事医学研究院 Timp3在焦虑抑郁症诊断中的应用
CN115287346A (zh) * 2022-05-26 2022-11-04 中山大学深圳研究院 急性心梗早期检测标记物及检测试剂盒
CN116059328A (zh) * 2022-09-14 2023-05-05 深圳先进技术研究院 Timp3重组蛋白用于制备抑制高血压肾透明细胞癌的制剂的应用
TW202444922A (zh) 2023-03-31 2024-11-16 國立大學法人大阪大學 用於預測敗血症患者之預後的生物標記及其用途
CN120053650A (zh) * 2025-01-23 2025-05-30 中南大学湘雅三医院 Mmp10抑制剂在制备防治血管钙化的产品中的应用
CN122506149A (zh) * 2025-02-28 2026-08-04 中国医学科学院阜外医院 评估肥厚型心肌病患者手术预后的代谢标志物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032648A1 (en) * 1995-04-11 1996-10-17 Spectral Diagnostics, Inc. Method and device for diagnosing and distinguishing chest pain in early onset thereof
WO2000052476A1 (en) * 1999-02-26 2000-09-08 Skye Pharmatech Incorported Method for diagnosing and distinguishing stroke
WO2002023191A1 (en) * 2000-09-12 2002-03-21 University Of Sydney Diagnostic assay
WO2002083913A1 (en) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
WO2002089657A2 (en) * 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
IL126544A (en) * 1996-04-25 2004-08-31 Genicon Sciences Inc Analyte assay using scattered-light detectable particles
AU1630501A (en) * 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032648A1 (en) * 1995-04-11 1996-10-17 Spectral Diagnostics, Inc. Method and device for diagnosing and distinguishing chest pain in early onset thereof
WO2000052476A1 (en) * 1999-02-26 2000-09-08 Skye Pharmatech Incorported Method for diagnosing and distinguishing stroke
WO2002023191A1 (en) * 2000-09-12 2002-03-21 University Of Sydney Diagnostic assay
WO2002083913A1 (en) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
WO2002089657A2 (en) * 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AY HAKAN ET AL: "Creatine kinase-MB elevation after stroke is not cardiac in origin: comparison with troponin T levels.", STROKE; A JOURNAL OF CEREBRAL CIRCULATION. JAN 2002, vol. 33, no. 1, January 2002 (2002-01-01), pages 286 - 289, XP002413932, ISSN: 1524-4628 *
FUTTERMAN L G ET AL: "Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A", AMERICAN JOURNAL OF CRITICAL CARE, THE ASSOCIATION, ALISO VIEJO, US, vol. 11, no. 2, March 2002 (2002-03-01), pages 168 - 172, XP008031012, ISSN: 1062-3264 *
LAMERS ET AL: "Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 92, 1995, pages 247 - 251, XP000910467, ISSN: 0001-6314 *
PERSSON L ET AL: "S-100 PROTEIN AND NEURON-SPECIFIC ENOLASE IN CEREBROSPINAL FLUID AND SERUM: MARKERS OF CELL DAMAGE IN HUMAN CENTRAL NERVOUS SYSTEM", STROKE, AMERICAN HEART ASSOCIATION, DALLAS TX, US, vol. 18, 1987, pages 911 - 918, XP000913410, ISSN: 0039-2499 *
QUINN DEBORAH A ET AL: "D-dimers in the diagnosis of pulmonary embolism", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 159, no. 5 PART 1, May 1999 (1999-05-01), pages 1445 - 1449, XP002413931, ISSN: 1073-449X *
SAGNELLA G A: "MEASUREMENT AND SIGNIFICANCE OF CIRCULATING NATRIURETIC PEPTIDES IN CARDIOVASCULAR DISEASE", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 95, no. 5, November 1998 (1998-11-01), pages 519 - 529, XP009052621, ISSN: 0143-5221 *
SONEL A ET AL: "PROSPECTIVE STUDY CORRELATING FIBRINOPEPTIDE A, TROPONIN I, MYOGLOBIN, AND MYOSIN LIGHT CHAIN LEVELS WITH EARLY AND LATE ISCHEMIC EVENTS IN CONSECUTIVE PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 102, no. 10, 5 September 2000 (2000-09-05), pages 1107 - 1113, XP009053500, ISSN: 0009-7322 *
VILLACORTA HUMBERTO ET AL: "The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea.", ARQUIVOS BRASILEIROS DE CARDIOLOGIA. DEC 2002, vol. 79, no. 6, December 2002 (2002-12-01), pages 569 - 572 , 564, XP002413933, ISSN: 0066-782X *

Also Published As

Publication number Publication date
JP2006526140A (ja) 2006-11-16
AU2003302340B8 (en) 2008-09-11
WO2004059293A2 (en) 2004-07-15
WO2004059293A3 (en) 2005-03-31
AU2003302340A1 (en) 2004-07-22
CA2511501A1 (en) 2004-07-15
AU2003302340B2 (en) 2008-08-21
EP1587955A2 (de) 2005-10-26

Similar Documents

Publication Publication Date Title
IL172986A0 (en) Hairpin -labeled probes and methods of use
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1549614A4 (de) Vaskulostatische mittel und verfahren zu deren anwendung
EP1701654A4 (de) Implantierbarer biosensor und anwendungsverfahren
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003253014A8 (en) Method for the diagnosis and differential diagnosis of neurological diseases
PL378294A1 (pl) Pochodne izochinolinowe i sposoby ich stosowania
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003278832A8 (en) Optical biosensors and methods of use thereof
EP1594424A4 (de) Ultraschallkatheter und herstellungsverfahren dafür
AU2003235676A1 (en) Tricyclic-bis-enone derivatives and methods of use thereof
EP1546112A4 (de) Imidazolopyridine und verfahren zu ihrer herstellung und verwendung
AU2003277164A8 (en) Imaging catheter with indicia and methods of use
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2003285254A1 (en) Drilling fluid and methods of use thereof
AU2003277259A8 (en) Immunoassay and method of use
TWI339662B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0206149D0 (en) Coupling system and method of use thereof
AU2003287802A1 (en) Palpometer and methods of use thereof
IL172704A0 (en) Salinosporamides and methods for use thereof
EP1551450A4 (de) Marker für die permeabilität der blutbarriere und verfahren zu ihrer verwendung
AU2003279800A8 (en) Sulfatases and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050725

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20070129BHEP

Ipc: C12Q 1/68 20060101AFI20050412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070209

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOSITE INCORPORATED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALERE SAN DIEGO, INC.

17Q First examination report despatched

Effective date: 20110413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110824